Insight Molecular Diagnostics Inc. (IMDX): EPS (Diluted)

Annual figures by period end, from SEC filings.

Stock splits: 1-for-20, first reflected in a filing dated 2023-08-10. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

-$1.65

Year ended 2025-12-31

2022-12-31 EPS (Diluted) (USD per share) 2025-12-31

Period ended	EPS (Diluted)	Change YoY	Source filing
2025-12-31	-$1.65	n/m	2026-03-26, From 2025-01-01
2024-12-31	-$4.66	n/m	2026-03-26, From 2024-01-01
2023-12-31	-$3.75	n/m	2025-03-24, From 2023-01-01
2022-12-31	-$13.25	n/a	2024-04-16, From 2022-01-01

EPS (Diluted) at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EPS (Diluted)	Change YoY
Insight Molecular Diagnostics Inc. (IMDX)	2025-12-31	-$1.65	n/m
Biomerica Inc (BMRA)	2026-05-31	-$1.30	n/m
Anbio Biotechnology (NNNN)	2025-12-31	$0.15	+162.5%
Aspira Women's Health Inc. (AWHL)	2025-12-31	-$0.37	n/m
Volitionrx Ltd (VNRX)	2024-12-31	-$0.31	n/m
Celldex Therapeutics, Inc. (CLDX)	2025-12-31	-$3.90	n/m
Immucell Corp (ICCC)	2025-12-31	-$0.12	n/m
Alpha Teknova, Inc. (TKNO)	2025-12-31	-$0.32	n/m
Intellia Therapeutics, Inc. (NTLA)	2025-12-31	-$3.81	n/m

Compare IMDX, BMRA, NNNN, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗